Lantheus Holdings (LNTH) EBITDA Margin (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly EBITDA Margin of 21.55% for Q1 2026, down 583.0% year-over-year from 4.46% in Q1 2025, and up 13.59% quarter-over-quarter from 18.97% in Q4 2025.
Lantheus Holdings (LNTH) EBITDA Margin (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported EBITDA Margin for 13 consecutive years, with 21.55% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 583.0% year-over-year to 21.55%; the TTM figure through Mar 2026 stood at 18.76% (down 1068.0% YoY), while the FY2025 annual figure was 20.16%, down 963.0% from the prior year.
- EBITDA Margin advanced to 21.55% in Q1 2026 per LNTH's latest filing, from 18.97% in the prior quarter.
- Across five years, EBITDA Margin topped out at 916.57% in Q4 2023 and bottomed at 65.24% in Q4 2022.
- Historically, EBITDA Margin has averaged 72.71% across 5 years, with a median of 28.21% in 2022.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 98181 bps — and 2024, when it tumbled 88746 bps.
- Lantheus Holdings' EBITDA Margin stood at 65.24% in 2022, then soared by 1505 bps to 916.57% in 2023, then sank by 97 bps to 29.12% in 2024, then tumbled by 35 bps to 18.97% in 2025, then rose by 14 bps to 21.55% in 2026.
- Business Quant data shows LNTH's EBITDA Margin at 21.55% in Q1 2026, 18.97% in Q4 2025, and 11.36% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | 25.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.82% |
| Mar 31, 2026 | 21.55% |
| Dec 31, 2025 | 18.97% |
| Sep 30, 2025 | 11.36% |
| Jun 30, 2025 | 23.27% |
| Mar 31, 2025 | 27.38% |
| Dec 31, 2024 | 29.12% |
| Sep 30, 2024 | 35.31% |
| Jun 30, 2024 | 26.07% |
| Mar 31, 2024 | 28.82% |
| Dec 31, 2023 | 916.57% |
| Sep 30, 2023 | 35.12% |
| Jun 30, 2023 | 38.59% |
| Mar 31, 2023 | -3.11% |
| Dec 31, 2022 | -65.24% |
| Sep 30, 2022 | 35.83% |
| Jun 30, 2022 | 28.25% |
| Mar 31, 2022 | 28.21% |
| Dec 31, 2021 | -27.27% |
| Sep 30, 2021 | -14.04% |